247 related articles for article (PubMed ID: 21178016)
1. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.
O'Reilly MK; Tian H; Paulson JC
J Immunol; 2011 Feb; 186(3):1554-63. PubMed ID: 21178016
[TBL] [Abstract][Full Text] [Related]
2. CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells.
Peng W; Paulson JC
J Am Chem Soc; 2017 Sep; 139(36):12450-12458. PubMed ID: 28829594
[TBL] [Abstract][Full Text] [Related]
3. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
Chen WC; Sigal DS; Saven A; Paulson JC
Leuk Lymphoma; 2012 Feb; 53(2):208-10. PubMed ID: 21756025
[TBL] [Abstract][Full Text] [Related]
4. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.
Tateno H; Li H; Schur MJ; Bovin N; Crocker PR; Wakarchuk WW; Paulson JC
Mol Cell Biol; 2007 Aug; 27(16):5699-710. PubMed ID: 17562860
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting of B-cell lymphoma with glycan ligands of CD22.
Chen WC; Completo GC; Sigal DS; Crocker PR; Saven A; Paulson JC
Blood; 2010 Jun; 115(23):4778-86. PubMed ID: 20181615
[TBL] [Abstract][Full Text] [Related]
6. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells.
Collins BE; Blixt O; Han S; Duong B; Li H; Nathan JK; Bovin N; Paulson JC
J Immunol; 2006 Sep; 177(5):2994-3003. PubMed ID: 16920935
[TBL] [Abstract][Full Text] [Related]
7. Sialic Acid Ligand Binding of CD22 and Siglec-G Determines Distinct B Cell Functions but Is Dispensable for B Cell Tolerance Induction.
Özgör L; Meyer SJ; Korn M; Terörde K; Nitschke L
J Immunol; 2018 Oct; 201(7):2107-2116. PubMed ID: 30143587
[TBL] [Abstract][Full Text] [Related]
8. Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.
Spiller F; Nycholat CM; Kikuchi C; Paulson JC; Macauley MS
J Immunol; 2018 Feb; 200(3):949-956. PubMed ID: 29288201
[TBL] [Abstract][Full Text] [Related]
9. In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.
Ramya TN; Weerapana E; Liao L; Zeng Y; Tateno H; Liao L; Yates JR; Cravatt BF; Paulson JC
Mol Cell Proteomics; 2010 Jun; 9(6):1339-51. PubMed ID: 20172905
[TBL] [Abstract][Full Text] [Related]
10. Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background.
Poe JC; Haas KM; Uchida J; Lee Y; Fujimoto M; Tedder TF
J Immunol; 2004 Feb; 172(4):2100-10. PubMed ID: 14764675
[TBL] [Abstract][Full Text] [Related]
11. Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.
Hong S; Yu C; Wang P; Shi Y; Cao W; Cheng B; Chapla DG; Ma Y; Li J; Rodrigues E; Narimatsu Y; Yates JR; Chen X; Clausen H; Moremen KW; Macauley MS; Paulson JC; Wu P
Angew Chem Int Ed Engl; 2021 Feb; 60(7):3603-3610. PubMed ID: 33314603
[TBL] [Abstract][Full Text] [Related]
12. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
Schweizer A; Wöhner M; Prescher H; Brossmer R; Nitschke L
Eur J Immunol; 2012 Oct; 42(10):2792-802. PubMed ID: 22777817
[TBL] [Abstract][Full Text] [Related]
13. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
Front Immunol; 2018; 9():820. PubMed ID: 29725338
[TBL] [Abstract][Full Text] [Related]
14. A reevaluation of CD22 expression in human lung cancer.
Pop LM; Barman S; Shao C; Poe JC; Venturi GM; Shelton JM; Pop IV; Gerber DE; Girard L; Liu XY; Behrens C; Rodriguez-Canales J; Liu H; Wistuba II; Richardson JA; Minna JD; Tedder TF; Vitetta ES
Cancer Res; 2014 Jan; 74(1):263-71. PubMed ID: 24395821
[TBL] [Abstract][Full Text] [Related]
15. Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.
Özgör L; Brandl C; Shock A; Nitschke L
Eur J Immunol; 2016 Sep; 46(9):2260-72. PubMed ID: 27352780
[TBL] [Abstract][Full Text] [Related]
16. Proximity labeling of cis-ligands of CD22/Siglec-2 reveals stepwise α2,6 sialic acid-dependent and -independent interactions.
Alborzian Deh Sheikh A; Akatsu C; Imamura A; Abdu-Allah HHM; Takematsu H; Ando H; Ishida H; Tsubata T
Biochem Biophys Res Commun; 2018 Jan; 495(1):854-859. PubMed ID: 29146181
[TBL] [Abstract][Full Text] [Related]
17. Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22.
Pfrengle F; Macauley MS; Kawasaki N; Paulson JC
J Immunol; 2013 Aug; 191(4):1724-31. PubMed ID: 23836061
[TBL] [Abstract][Full Text] [Related]
18. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking.
Han S; Collins BE; Bengtson P; Paulson JC
Nat Chem Biol; 2005 Jul; 1(2):93-7. PubMed ID: 16408005
[TBL] [Abstract][Full Text] [Related]
19. CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions.
Nakashima H; Hamaguchi Y; Watanabe R; Ishiura N; Kuwano Y; Okochi H; Takahashi Y; Tamaki K; Sato S; Tedder TF; Fujimoto M
J Immunol; 2010 May; 184(9):4637-45. PubMed ID: 20335532
[TBL] [Abstract][Full Text] [Related]
20. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling.
Collins BE; Smith BA; Bengtson P; Paulson JC
Nat Immunol; 2006 Feb; 7(2):199-206. PubMed ID: 16369536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
